random trial amsacrin rubidazon patient acut promyelocyt leukemia thirty-nin patient untreat acut promyelocyt leukemia apl rubidazon zorubicin day cytarabin ara day arm patient amsacrin amsa day ara day arm patient prophylaxi dissemin intravascular coagul platelet transfus heparin case leukem resist patient second cours day rubidazon amsa arm day ara complet remiss CR consolid cours drug induct mainten therapi year patient arm arm first CR initi characterist similar arm arm patient CR hypoplast death resist cours arm patient CR earli death cn bleed case ventricular fibril case resist leukemia cours differ CR rate arm signific arm disease-fre surviv df plateau month confid interv CI cr month arm df plateau month confid interv cr differ df signific allograft patient patient CR arm arm result amsa-ara combin inferior anthracycline-ara combin treatment apl df incid initi leukem resist studi number patient 